-
EPI-001: Reliable AR Inhibition Workflows
2026-09-30
A practical, scenario-based guide to using EPI-001 (SKU B6041) in androgen receptor signaling, viability, proliferation, and cytotoxicity workflows. It connects formulation, assay design, data interpretation, and supplier-selection considerations to evidence from prostate cancer and AR-positive TNBC research.
-
RIPA Lysis Buffer Strong: Practical Workflow
2026-09-30
RIPA Lysis Buffer Strong (SKU K1120) provides robust detergent-based extraction from animal cells and tissues for Western blotting, immunoprecipitation, ELISA, and kinase workflows. Its inhibitor-free formulation supports customized protection strategies, but the strong detergents may reduce compatibility with native protein-complex studies and detergent-sensitive downstream assays.
-
Danazol: Mechanism, Models, and Research Workflow
2026-09-29
Danazol, also known as Danocrine, is a synthetic weak androgenic steroid used to investigate androgen receptor signaling, steroidogenesis, and hypothalamic–pituitary–gonadal regulation. Its strongest research value is as a mechanistic endocrine perturbagen, while rat puberty findings and prostate cancer research require careful separation from clinical conclusions.
-
Nonivamide (Capsaicin Analog) in Cell Assays
2026-09-29
This scenario-based guide explains how Nonivamide (Capsaicin Analog), SKU A3278, can support reproducible TRPV1-focused viability, proliferation, and apoptosis workflows. It covers solvent compatibility, concentration planning, orthogonal readouts, and practical supplier-selection criteria for cancer research.
-
TBST Workflows for uPAR–uPA Immunoassays
2026-09-28
TBST combines buffered salt conditions with Tween 20 to support cleaner Western blot, immunofluorescence, immunohistochemistry, and immunocytochemistry workflows. This guide connects practical buffer optimization with the conformation-aware uPAR–uPA inhibitor study, showing how controlled washing can improve interpretability without being mistaken for proof of mechanism.
-
Marein Blocks ABCG2 to Restore Chemosensitivity
2026-09-28
A 2024 study identifies marein, a natural product from Coreopsis tinctoria, as a competitive inhibitor of ABCG2 that increases intracellular exposure to transporter-substrate drugs. Cellular response, drug accumulation, and target-engagement experiments connect this effect with restored sensitivity to topotecan, mitoxantrone, and olaparib in ABCG2-expressing cancer cells.
-
SEMA3E Drives Beige Adipocyte Thermogenesis in Mice
2026-09-27
The study identifies SEMA3E as a regulator of beige adipocyte differentiation and thermogenic capacity, linking its effects to mitochondrial respiration and β-catenin turnover. Cell-based perturbations, mouse interventions, and pathway-rescue experiments provide converging evidence, while leaving the precise molecular connection and relevance to human adipose tissue open.
-
Ferroptosis Translation: From Mitochondria to Models
2026-09-26
Mitochondrial calcium signaling and GPX4 acetylation add a mechanistic dimension to ferroptosis research. This article turns that insight into a practical framework for validating ferroptosis assays and evaluating Liproxstatin-1 HCl in preclinical models.
-
Abiraterone Acetate in 3D Prostate Cancer Research
2026-09-25
Pair a potent CYP17 inhibitor with patient-derived prostate spheroids to test how model context shapes drug response. This workflow emphasizes vehicle controls, dose-ranging, and target-relevant readouts—especially important because a published organ-confined spheroid study reported no effect from abiraterone under its tested conditions.
-
CD38 CAR Binder Structures Guide Affinity Tuning
2026-09-25
Cheng et al. show that the CD38 binders RP02 and 028 engage different antigen surfaces, with 028 also inhibiting CD38 cyclase activity through a distinct structural mechanism. Structure-guided attenuation of 028 reduced CAR-T fratricide while retaining tumor-cell cytotoxicity, illustrating how epitope geometry and affinity can inform cellular selectivity.
-
Abiraterone acetate in prostate spheroid research
2026-09-24
Use Abiraterone acetate to probe CYP17-dependent androgen biosynthesis in patient-derived prostate spheroids, while separating target engagement from changes in viability. A practical workflow pairs careful compound handling with donor-aware controls and orthogonal readouts—important because organ-confined spheroids did not respond to abiraterone in the cited study.
-
Indomethacin as a Probe of Beige-Fat Signaling
2026-09-24
Indomethacin is a nonsteroidal anti-inflammatory drug with actions that can complicate studies of adipocyte thermogenesis. This article examines how to use it cautiously to separate COX-dependent effects from SEMA3E–β-catenin biology in beige-fat research.
-
MDM1–p53 Signaling and CRC Chemoradiotherapy Response
2026-09-23
A 2025 study links MDM1 expression to colorectal cancer cell sensitivity to chemoradiotherapy through YBX1-associated regulation of TP53 and apoptosis. The findings position MDM1 as a candidate response biomarker and provide a mechanistic basis for testing strategies that restore treatment sensitivity, while leaving clinical validation and treatment-specific parameters to future work.
-
Hydroxychloroquine Sulfate Workflow Guide
2026-09-23
Hydroxychloroquine Sulfate (SKU B4874) provides an aqueous research reagent for examining autophagy pathway modulation and TLR7/9-dependent immune signaling. It is appropriate for autoimmune disease research and related cell or animal workflows, but not for protocols requiring DMSO or ethanol solubility or long-term storage of prepared solutions.
-
Wnt-C59: A Translational Map for Wnt Control
2026-09-22
Wnt-C59 offers a precise way to interrogate PORCN-dependent Wnt ligand secretion, while recent work on lithium-engineered exosomes shows why pathway modulation must be interpreted in its biological context. This article connects cancer-focused Wnt inhibition with regenerative research and outlines a practical framework for translational validation.